Vitamin D Deficiency (Rickets & Osteomalacia)

Overview & Definition

Vitamin D is a prohormone rather than a vitamin in the strict sense, because the body can synthesise it entirely in the skin under ultraviolet-B (UVB) light. It occupies the centre of a tightly regulated calcium–phosphate–parathyroid hormone (PTH)–bone axis whose purpose is to maintain extracellular calcium and phosphate concentrations within narrow limits and to permit normal mineralisation of newly formed osteoid and growth-plate cartilage. When the supply of vitamin D — whether cutaneous or dietary — is inadequate, gut calcium and phosphate absorption fall, the serum calcium is defended at the cost of secondary hyperparathyroidism, and unmineralised osteoid accumulates. In the growing skeleton this manifests as nutritional rickets; in the mature skeleton as osteomalacia.[1][2]

Vitamin D deficiency is best understood as a continuum of severity rather than a binary state, because the biochemical and clinical features emerge in sequence as the vitamin D store depletes. The first detectable abnormality is a fall in 25-hydroxyvitamin D; next comes a rise in PTH (secondary hyperparathyroidism) with renal phosphate wasting; only later do alkaline phosphatase rise, radiographic changes appear and symptoms develop. Recognising the early, biochemical stage — before irreversible skeletal deformity — is the clinical art. [1]

The clinical stakes are real but largely preventable and reversible. Severe infantile rickets can present with hypocalcaemic seizures, laryngeal stridor and dilated cardiomyopathy, and nutritional rickets remains endemic in South Asia, the Middle East and parts of Africa despite being entirely preventable by a cheap, safe daily supplement. In adults, undiagnosed osteomalacia is a common and treatable cause of bone pain, proximal weakness and falls, frequently mistaken for polymyalgia rheumatica, fibromyalgia, inflammatory myopathy or metastatic bone disease. [1]

Classification

Vitamin D status is classified by the serum 25-hydroxyvitamin D concentration, the storage metabolite. Thresholds differ between guidelines; the ladder used here follows the widely applied convention that under 50 nmol/L (20 ng/mL) defines deficiency, with severe deficiency under 30 nmol/L (12 ng/mL), and 50 nmol/L or above as the treatment goal — the same level the IOM/NAM RDAs (600 to 800 IU/day) are built to cover. To convert nmol/L to ng/mL, divide by 2.5.[15][8]

[15] [8] [3]

A second classification axis — central to paediatric rickets — separates calcipenic rickets (vitamin D and/or calcium deficiency, with low/normal calcium, low phosphate, high PTH) from phosphopenic rickets (renal phosphate wasting — X-linked hypophosphataemia from PHEX, tumour-induced osteomalacia from FGF23 — with low phosphate, normal calcium, normal or low PTH). The distinction is fundamental because the treatments diverge: calcipenic rickets responds to vitamin D and calcium, whereas phosphopenic rickets requires oral phosphate and active vitamin D and is worsened by calcium/vitamin D alone.[1]

Epidemiology & Risk Factors

Vitamin D deficiency is the commonest nutritional deficiency worldwide, with an estimated 1 billion people affected and around 50 per cent of the global population classified as insufficient. Subclinical deficiency is so prevalent in temperate latitudes — particularly through winter and spring — that it is best regarded as the default state in several high-risk groups unless actively supplemented.[1][2]

The high-risk groups the examiner expects you to name are predictable because they cluster around the two sources of vitamin D — the skin and the gut — and the three metabolic steps that activate it. In the skin, melanin competes for UVB photons, so people with dark South Asian, African, African-Caribbean or Middle Eastern skin need substantially longer sun exposure to synthesise the same amount of vitamin D3 as a fair-skinned person at the same latitude. Cultural and religious covering, housebound or institutionalised status, high latitude and winter season (in Boston, 42 degrees N, sunlight made no previtamin D3 from November through February; in Edmonton, 52 degrees N, from October through March), air pollution, sunscreen and window glass all reduce cutaneous synthesis. [13][1]

[13] [15] [8] [10] [11] [14] [9]

In the gut, malabsorption is the dominant mechanism — coeliac disease, inflammatory bowel disease, post-bariatric surgery (Roux-en-Y, sleeve gastrectomy), cystic fibrosis, chronic pancreatitis, short bowel syndrome and cholestatic liver disease all impair the fat-soluble absorption of vitamin D. Obesity lowers the achieved 25-OH-D per unit dose — a randomised dose-response study found about 40 per cent higher intake is needed in obesity to reach the same 25-OH-D concentration; nephrotic syndrome wastes vitamin D-binding protein (DBP) in the urine. Exclusive breastfeeding is a frequent infant cause, because breast milk alone does not provide enough vitamin D, so breastfed infants need direct supplementation (400 IU/day) in the first year. Prematurity compounds this because the fetal vitamin D store is laid down in the third trimester. [16][14][1]

The metabolic causes target the liver (impaired 25-hydroxylation in cirrhosis), the kidney (impaired 1-alpha-hydroxylation in chronic kidney disease — the single most important adult cause), and drug-induced catabolism (enzyme inducers — phenytoin, carbamazepine, phenobarbitone, rifampicin, isoniazid, some antiretrovirals such as efavirenz, and high-dose glucocorticoids — which up-regulate CYP24A1 and accelerate vitamin D degradation). Age itself is a risk: skin 7-dehydrocholesterol content falls by more than half between ages 20 and 70, and elderly, housebound populations combine reduced synthesis, reduced intake and reduced sun exposure. [1]

Pathophysiology

Vitamin D metabolism is a three-organ cascade — skin, liver, kidney — whose product, calcitriol (1,25-dihydroxyvitamin D), acts through a nuclear receptor on the gut, bone, kidney and parathyroid gland. Understanding each step is the key to understanding every cause, every laboratory abnormality and every treatment choice.[1][2]

[1]

Calcitriol acts by binding the vitamin D receptor (VDR), a nuclear receptor that heterodimerises with the retinoid X receptor (RXR) and binds vitamin D response elements in target genes. In the intestine it transcriptionally up-regulates TRPV6 (apical calcium channel), calbindin-D9k (cytosolic calcium shuttle) and the Ca-ATPase (PMCA1b) — together doubling-to-tripling calcium absorption, from about 10 to 15 per cent at baseline to 30 to 40 per cent when calcitriol is abundant. Phosphate absorption rises in parallel through NaPi-IIb up-regulation. In bone, calcitriol permits — and is permissive for — normal osteoid mineralisation, and modulates osteoblast RANKL and osteoprotegerin (OPG) expression. In the kidney, calcitriol augments distal calcium reabsorption through TRPV5 and calbindin-D28k. In the parathyroid gland, calcitriol suppresses PTH gene transcription and parathyroid cell proliferation. [1]

[1]

The failure cascade follows directly. When calcitriol falls, gut calcium absorption drops to a level too low to defend serum calcium. The parathyroid CaSR senses the falling ionised calcium within seconds and PTH rises — the appropriate secondary hyperparathyroidism of vitamin D deficiency. PTH mobilises calcium from bone (driving osteoclast-mediated resorption and a rise in alkaline phosphatase from coupled osteoblast activity) and wastes phosphate in the urine by down-regulating NaPi-2a in the proximal tubule — which is why phosphate falls even though bone resorption releases it. The serum calcium is partially defended by PTH and so reads low or low-normal, never profoundly low until stores are exhausted. Meanwhile osteoid continues to be laid down by osteoblasts but is not mineralised, widening the osteoid seam and producing the histological signature of osteomalacia. In the growing child the same defect strikes the hypertrophic zone of the growth plate, where unmineralised cartilage accumulates, the metaphysis widens, and the softened bone bows under weight — the radiographic and clinical picture of rickets. [1]

Calcitriol also has extra-skeletal actions — immunomodulation (macrophage-expressed CYP27B1 locally activates vitamin D to drive cathelicidin and beta-defensin antimicrobial peptides), cell differentiation and anti-proliferation, renin suppression, and modulation of insulin secretion. These observations underpinned two decades of epidemiological associations linking low 25-OH-D to cardiovascular disease, cancer, diabetes and infections — associations that, as the Evidence section shows, have not been confirmed by large randomised trials of supplementation.[6][7]

Causes

The causes of vitamin D deficiency map onto the synthesis chain described above and are best memorised as a single mnemonic. The trick to scoring well is to name the mechanism (synthesis failure, intake failure, malabsorption, impaired 25-hydroxylation, impaired 1-alpha-hydroxylation, increased catabolism, sequestration) as well as the cause.[1][2]

[13] [14] [16] [1]

The rare genetic causes deserve a focused mention because they explain the refractory rickets stem. Vitamin-D-dependent rickets type 1 (VDDR-I) is autosomal recessive loss of CYP27B1 — the kidney cannot 1-alpha-hydroxylate, so calcitriol is low and the picture resembles severe nutritional deficiency despite adequate intake; it responds dramatically to physiological doses of calcitriol. Vitamin-D-dependent rickets type 2 (VDDR-II, hereditary vitamin-D-resistant rickets) is autosomal recessive loss-of-function of the VDR — calcitriol is high but ineffective; patients have alopecia (a key discriminating sign) and require very high doses of calcium and calcitriol. These must be distinguished from X-linked hypophosphataemic rickets (PHEX mutation), a phosphopenic rickets driven by FGF23 excess, in which calcium and PTH are normal and phosphate is low — the treatment is oral phosphate plus calcitriol, not vitamin D alone.[1]

Clinical Presentation

The clinical face of vitamin D deficiency depends on age (growing vs mature skeleton) and on severity. Many adults are entirely asymptomatic and the diagnosis is made on a screening 25-OH-D; the symptomatic extremes are rickets in children and osteomalacia in adults, with symptomatic hypocalcaemia as the acute emergency that crosses both. [1]

Rickets — the growing skeleton

Rickets is the failure of mineralisation at the growth plate (physis). The clinical features cluster into skeletal, dental, neuromuscular and acute hypocalcaemic groups.[1]

The head shows craniotabes (soft, ping-pong-ball skull, best felt over the occiput and parietal bones, in infants under 1 year), frontal bossing, delayed fontanelle closure (anterior fontanelle still open beyond 18 months), and delayed dentition with enamel hypoplasia and early caries. The chest has the rachitic rosary — palpable, beaded, anterior costochondral junctions that may be visible and tender — and a Harrison sulcus, a horizontal groove along the line of diaphragmatic insertion produced by the pull of the diaphragm on a softened rib cage. The limbs are the most examined: widening of the wrists (distal radius and ulna) and ankles, genu varum (bow legs) or genu valgum (knock knees), anterior bowing of the tibia, coxa vara, double malleoli, greenstick fractures, and reluctance to walk or a delayed walking milestone. The spine may show kyphoscoliosis and the pelvis flattens (forward projection of the promontory), which in adolescent girls can obstruct future vaginal delivery. Short stature (stunting) is common and is a key population-level marker of endemic nutritional rickets. [1]

The acute hypocalcaemic presentation is the emergency to remember. Exclusively breastfed infants of vitamin-D-deficient mothers, typically aged 3 to 18 months, can present with generalised tonic-clonic seizures, laryngeal stridor, carpopedal spasm, apnoea or cardiac failure — and rarely dilated cardiomyopathy and sudden death. An infant presenting with an afebrile seizure, particularly of South Asian or African origin and exclusively breastfed, must have calcium, magnesium, 25-OH-D, PTH and ALP checked before discharge; missing severe infantile rickets can be fatal. [1]

Osteomalacia — the mature skeleton

Osteomalacia is the failure of mineralisation of trabecular and cortical bone. Because the growth plates are fused, there is no metaphyseal cupping; instead, the patient complains of diffuse, dull, aching bone pain — typically in the lower back, pelvis, ribs and lower legs — that is worse on activity and reproduced by bone palpation (especially the tibial shafts and ribs).[2]

The signature feature is a proximal muscle weakness (a true myopathy of vitamin D deficiency, not a primary muscle disease). Patients describe difficulty rising from a low chair or the floor, climbing stairs, combing their hair or lifting objects overhead, and adopt a characteristic waddling (Trendelenburg-like) gait. The weakness is proximal and symmetrical, easily mistaken for polymyalgia rheumatica, inflammatory myositis, statin myopathy or thyroid myopathy — but the creatine kinase is normal (muscle is structurally intact; the defect is calcium-dependent muscle function) and the 25-OH-D is low. [1]

Pathological and insufficiency fractures occur, particularly at sites of Looser zones (see Investigations). Vertebral involvement causes loss of height and kyphosis. The disease is frequently mistaken for osteoporosis on DEXA — both lower bone mineral density — but osteomalacia has a low or normal calcium with high PTH that osteoporosis does not, and the treatment is different. [1]

Atypical and occult presentations

Examiners test the corners. The elderly, housebound patient may present with falls, proximal weakness, low-trauma fracture or unexplained bone pain rather than a textbook osteomalacia picture. The post-bariatric surgery patient (especially after Roux-en-Y or duodenal switch) develops deficiency months to years after surgery and may also have calcium, iron, B12 and thiamine deficiency. The institutionalised or chronically ill patient on long-term anticonvulsants has a drug-induced component layered on top of sun deprivation. The pregnant or lactating woman with deep, pelvic, weight-bearing pain may have transient osteoporosis of pregnancy or osteomalacia. The dark-skinned immigrant to a temperate climate often presents in the first spring after migration with biochemically overt deficiency. Cardiomyopathy in an exclusively breastfed infant is an under-recognised and occasionally fatal presentation. [1]

Differential Diagnosis

The differential is built by asking two questions: (1) is the bone disease rickets/osteomalacia at all? and (2) if it is, is it calcipenic or phosphopenic? The laboratory panel — especially calcium, phosphate, PTH and ALP — answers both.[1]

Three pitfalls deserve emphasis. Hypophosphatasia (loss-of-function ALPL) presents with rachitic-like bone changes but a LOW alkaline phosphatase — the opposite of nutritional rickets — and is worsened by bisphosphonates; genetic testing and ALP are essential before treating "rickets" with a low ALP. Primary hyperparathyroidism shares high PTH and high ALP with vitamin D deficiency, but has HIGH calcium (not low) and is often discovered incidentally. Metastatic bone disease and multiple myeloma in older adults produce bone pain, fractures and lytic lesions that can superficially resemble osteomalacia; an immunoglobulin/serum-free light-chain screen, prostate-specific antigen and a myeloma screen are appropriate in the atypical older adult. [1]

Clinical & Bedside Assessment

The bedside assessment has three goals: identify the skeletal and muscular features, screen for the underlying cause, and detect the acute hypocalcaemic emergency. Begin with the tempo of presentation (acute seizure vs chronic bone pain) and the risk-factor history (sunlight, diet, dark skin, malabsorption symptoms — diarrhoea, weight loss, steatorrhoea — bariatric surgery, medications, CKD, family history). [1]

In the child with suspected rickets the examination is systematic. Head: feel for craniotabes (occipital/parietal softening), inspect for frontal bossing, check fontanelle size (delayed closure beyond 18 months) and the teeth (enamel hypoplasia, delayed eruption). Chest: palpate the costochondral junctions for the rachitic rosary and inspect for Harrison sulcus. Abdomen: hepatosplenomegaly may suggest malabsorption. Limbs: measure and palpate the wrists, ankles, knees for widening; observe genu varum/valgum with the child standing (intermalleolar/intercondylar distance); watch the gait. Growth: plot height and weight (stunting is a key marker). Neurology: tone, power, deep tendon reflexes (hypotonia is common). [1]

In the adult with suspected osteomalacia the examination focuses on the gait (waddling), the proximal muscle power (rising from a chair, stair-climbing, shoulder abduction), bone tenderness (rib and tibial shaft pressure reproduces the pain), the spine (kyphosis, vertebral tenderness) and a search for fractures (rib, pubic ramus, femoral neck). Look for skin and dietary clues (sun-avoidance, cultural covering), an abdominal scar (prior bariatric or bowel surgery), signs of chronic liver or kidney disease, and a drug history for enzyme inducers. Neuromuscular irritability signs (Chvostek, Trousseau) are positive only if hypocalcaemic; their presence indicates severe deficiency. [1]

In the acutely hypocalcaemic infant (seizure, stridor, apnoea, cardiac failure) the assessment is resuscitative: airway, breathing, circulation, ECG (prolonged QTc), IV access, bedside glucose and a stat calcium before treatment. [1]

Investigations

The diagnosis of vitamin D deficiency rests on a short panel — a single 25-hydroxyvitamin D level with calcium, phosphate, PTH and alkaline phosphatase — supported by radiographs in symptomatic bone disease. The trick is to interpret the panel together, because each abnormality points to a different point in the cascade.[1][2]

The blood panel — and what each result means

The single best marker of vitamin D status is 25-hydroxyvitamin D (calcidiol). It is the storage form, has a half-life of 2 to 3 weeks, reflects total-body input from both skin and diet, and the hepatic 25-hydroxylation step is substrate-driven (little regulated), so its level mirrors supply rather than activation. Do NOT measure calcitriol (1,25-(OH)2-D) to diagnose deficiency: it can be normal or even elevated in severe deficiency because secondary hyperparathyroidism drives renal 1-alpha-hydroxylase, masking the deficiency. Calcitriol measurement is reserved for CKD, hypercalcaemia of granulomatous disease (sarcoid, TB, lymphoma), suspected VDDR-II, and hypercalcaemia of malignancy.[2]

The classical biochemical tetrad of established vitamin D deficiency is: low or normal calcium (defended by PTH until late), low phosphate (PTH-driven phosphaturia), high PTH (appropriate secondary hyperparathyroidism) and high alkaline phosphatase (osteoblast activity coupled to PTH-driven resorption). The pattern distinguishes deficiency from primary hyperparathyroidism (high calcium, high PTH), CKD-MBD (low calcium, high phosphate, high PTH) and osteoporosis (normal calcium, phosphate, PTH and ALP). [1]

[15] [12]

Always also send a renal profile (eGFR — CKD is the commonest metabolic cause), liver function (cirrhosis impairs 25-hydroxylation), albumin (correct the calcium), magnesium (hypomagnesaemia causes refractory hypocalcaemia), and a FBC (anaemia may suggest malabsorption). In suspected malabsorption add coeliac serology (anti-tissue transglutaminase IgA plus total IgA), and consider faecal calprotectin or endoscopy. In the refractory case, send 1,25-(OH)2-D (high in VDDR-II, low in VDDR-I) and genetic testing (PHEX, CYP27B1, VDR, ALPL). [1]

Radiographs and bone imaging

Wrist and knee radiographs in the child show the pathognomonic cupped, frayed and widened metaphyses — the unmineralised hypertrophic cartilage of the growth plate bulges and splays under weight. The distal radial and ulnar metaphyses are the most reliable site. Other features include generalised osteopenia, bowing of long bones, greenstick fractures, delayed epiphyseal appearance, skull craniotabes and the rachitic rosary on chest X-ray. [1]

Pelvic and long-bone radiographs in the adult show Looser zones (pseudofractures) — symmetrical, narrow, transverse, radiolucent bands perpendicular to and through the cortex, without displacement, classically at the medial femoral neck, pubic rami, ribs, lateral scapula and clavicle. Extensive Looser zones are sometimes called Milkman syndrome. Other findings include osteopenia, codfish (biconcave) vertebrae and a triradiate pelvis (inlet deformity from softened bones). [1]

DEXA shows low bone mineral density (low T-score in adults, low Z-score in children and premenopausal women) and may be indistinguishable from osteoporosis — but the biochemistry distinguishes the two. Bone turnover markers (CTX, P1NP) are typically elevated. Tetracycline-labelled transiliac bone biopsy is the gold standard — demonstrating increased osteoid width and prolonged mineralisation lag time — but is rarely needed in clinical practice; it is reserved for atypical or refractory cases, suspected aluminium-related bone disease in dialysis, or before labelling chronic kidney disease bone disease. [1]

Self-test — A 28-year-old vegan woman with Crohn's disease has diffuse bone pain, waddling gait and difficulty climbing stairs. 25-OH-D 14 nmol/L, calcium 2.05 mmol/L, phosphate 0.6 mmol/L, PTH 12 pmol/L, ALP 320 U/L. What is the pattern and the next imaging test?

The biochemical pattern is the classical tetrad of calcipenic osteomalacia — low 25-OH-D, low/normal calcium, low phosphate (PTH phosphaturia), high PTH (secondary hyperparathyroidism), high ALP (osteoblast activity). The cause is Crohn's-related malabsorption layered on a vegan diet. The next imaging test is a pelvic and proximal femoral radiograph to look for Looser zones (pseudofractures) — symmetrical transverse radiolucent lines perpendicular to the cortex at the medial femoral neck, pubic rami and ribs. Treat with high-dose cholecalciferol daily for at least 12 weeks at higher-than-standard dosing, adequate calcium (diet or supplement), treat the Crohn's, and consider active vitamin D if cholecalciferol cannot sustain levels.[12][16]

[1]

Management — Resuscitation

[12]

Most vitamin D deficiency is not an emergency and is managed electively. The resuscitative scenarios are symptomatic hypocalcaemia (seizure, tetany, laryngeal stridor, prolonged QT, cardiomyopathy) and severe infantile rickets with hypocalcaemia.[1][2]

[12] [10]

The cardiomyopathy of severe infantile rickets is a dilated cardiomyopathy from chronic hypocalcaemia, occasionally the presenting feature, and is reversible with calcium and vitamin D over weeks; do not assume a viral aetiology in an at-risk infant without checking calcium and 25-OH-D. [1]

Management — Definitive & Stepwise

Once hypocalcaemia is excluded or treated, the definitive management has four pillars: (1) replace the vitamin D store with a loading dose then maintenance, (2) ensure adequate calcium, (3) use active vitamin D when 1-alpha-hydroxylation is impaired (CKD, severe liver disease, VDDR-I/II), and (4) treat the underlying cause.[1][2]

Step 1 — Replace the vitamin D store

The principle is a high treatment dose to replete the store, followed by maintenance to sustain it. Either cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2) is recommended for treating deficiency; a systematic review of cholecalciferol regimens found the best schedule was an initial large dose — oral 50,000 IU weekly for 8 weeks, oral 200,000 IU monthly, or IM 600,000 IU monthly — followed by maintenance of 50,000 IU monthly or bimonthly. Both are inactive prohormones that require hepatic 25-hydroxylation and (for full activity) renal 1-alpha-hydroxylation, so they are inappropriate as sole therapy when 1-alpha-hydroxylation is impaired.[2][10]

[12] [10] [2] [8] [3] [11] [7] [16] [9]

Step 2 — Treat the underlying cause

Cure the deficiency and it recurs unless the cause is addressed. Coeliac disease needs a gluten-free diet and a malabsorption work-up. Inflammatory bowel disease needs disease control. Post-bariatric patients need lifelong higher-dose supplementation and micronutrient surveillance. Cholestatic liver disease may benefit from a water-miscible vitamin D preparation. CKD needs calcitriol and a CKD-MBD pathway (phosphate binders, vitamin D analogues, calcimimetics). Enzyme-inducing drugs should be reviewed and the dose of vitamin D increased where they cannot be stopped. Sun exposure advice (15 minutes of midday sun on face and forearms, May to September, lighter-skinned; longer for darker skin, without sunscreen during that window) and dietary advice (oily fish — salmon, mackerel, sardines; eggs; fortified foods; cod-liver oil) complete the package. [1]

Step 3 — Monitor

Recheck 25-OH-D at 3 to 4 months after starting loading (the store takes this long to plateau), then annually in high-risk groups. Track calcium, phosphate, ALP and PTH to confirm biochemical healing — ALP falls and PTH normalises as rickets heals, often before radiographic resolution. DEXA in adults with low bone density. In children, repeat wrist/knee radiographs at 3 months to document metaphyseal healing, and monitor growth. Calcitriol therapy in CKD requires close calcium monitoring (every 1 to 2 weeks during titration) to avoid hypercalcaemia. [1]

Specific Subtypes & Scenarios

Nutritional rickets in exclusively breastfed infants is the global prototype. Breast milk alone does not provide enough vitamin D, so exclusively or partially breastfed infants are at risk unless supplemented — 400 IU/day given directly to the infant in the first year achieves 25-OH-D over 50 nmol/L, with higher treatment doses for established deficiency. Maternal postpartum supplementation is a studied alternative: a systematic review found it achieves infant 25-OH-D that is similar or only modestly lower than direct infant daily dosing.[11][14]

Vitamin D deficiency in CKD is fundamentally a problem of lost 1-alpha-hydroxylase. As kidney function declines, calcitriol production falls, phosphate retention rises, and secondary hyperparathyroidism (CKD-MBD) develops. Native cholecalciferol repletes the store but cannot correct the calcitriol deficit, so active vitamin D analogues, phosphate control and — for refractory secondary hyperparathyroidism — calcimimetics are added under a CKD-MBD pathway, with close calcium monitoring.[2]

Malabsorption (coeliac, post-bariatric, cystic fibrosis, short bowel) combines impaired absorption with steatorrhoea-driven fat-soluble vitamin loss. Standard doses fail; 2 to 3 times the maintenance dose (or a water-miscible preparation) is needed, with periodic monitoring. The cause should be treated (gluten-free diet for coeliac; disease control for Crohn's) to restore absorptive capacity.[2]

Obesity lowers the 25-OH-D achieved per unit dose. A randomised dose-response study in adults with BMI of 35 or more found the vitamin D3 response slope was significantly lower than in non-obese adults (0.398 vs 0.66 nmol/L per microgram/day) — roughly 40 per cent higher intake is needed to reach the same 25-OH-D concentration. Weight loss raises 25-OH-D, but supplementation is needed in the interim.[16]

Pregnancy and lactation increase vitamin D requirement, and pregnant and lactating women are recognised at-risk groups for supplementation in international guidance. Severe maternal deficiency is associated with neonatal hypocalcaemia and congenital rickets — repletion is recommended when deficiency is identified.[1][12]

Drug-induced deficiency (enzyme inducers — phenytoin, carbamazepine, phenobarbitone, rifampicin, efavirenz, glucocorticoids) accelerates catabolism via CYP24A1. Increase the maintenance dose 2 to 3 fold and monitor; review the drug history in any unexplained deficiency. [1]

Vitamin-D-dependent rickets type 1 and 2 are rare autosomal recessive disorders presenting in infancy with severe, refractory rickets. VDDR-I (CYP27B1 loss) has low calcitriol and responds to physiological calcitriol replacement. VDDR-II (VDR loss-of-function) has high calcitriol, alopecia, and requires very high-dose calcium and calcitriol; some respond only to IV calcium infusions in childhood.[1]

Complications & Pitfalls

The acute complications of severe deficiency are symptomatic hypocalcaemia (seizures, tetany, laryngeal stridor, prolonged QT, torsades de pointes, hypotension), dilated cardiomyopathy in infants, and pathological fractures through Looser zones or softened metaphyses. These are the indications for urgent IV calcium and high-dose vitamin D.[1]

The chronic complications of untreated disease are permanent skeletal deformity (bowing, kyphoscoliosis, triradiate pelvis — the latter obstructing future vaginal delivery), short stature, proximal myopathy with falls and fracture, secondary hyperparathyroidism driving further bone resorption, dental caries and enamel defects, and (in CKD) progression to renal osteodystrophy with vascular calcification. [1]

The pitfalls of treatment are several and examinable. Treating without calcium fails to heal rickets — oral calcium should routinely accompany vitamin D. Giving native colecalciferol alone in CKD is futile because 1-alpha-hydroxylation is impaired — use active vitamin D. Annual mega-dose bolus (500,000 IU) in older women paradoxically increased falls (rate ratio 1.15) and fractures (rate ratio 1.26) (Sanders 2010, JAMA), with the highest fall risk in the first 3 months after the bolus — daily or weekly dosing is safer.[9][12] Over-treatment produces hypercalcaemia (nausea, vomiting, polyuria, constipation, confusion, nephrocalcinosis) and hyperphosphataemia — rare with native vitamin D at standard doses but a real risk of active vitamin D in CKD. The hungry-bone phenomenon during early treatment of severe rickets/osteomalacia can transiently worsen hypocalcaemia as the skeleton avidly re-mineralises; monitor closely and titrate calcium. Missing the diagnosis of hypophosphatasia (low ALP) and treating with bisphosphonates can be catastrophic.

Prognosis & Disposition

Vitamin D deficiency responds rapidly and completely to replacement. Biochemical markers (ALP, PTH) begin to normalise within weeks; radiographic healing of rickets is visible at 3 months; bone pain and muscle weakness improve within 4 to 8 weeks; and 25-OH-D reaches its plateau at 3 to 4 months after loading. Residual skeletal deformity (bowing, kyphosis, short stature) may persist in children treated late but usually remodels over years if growth continues; severe pelvic deformity in adolescent girls may require caesarean delivery.[1][2]

Disposition depends on context. The asymptomatic adult with screening-detected deficiency is managed entirely in primary care with oral colecalciferol. The symptomatic adult or child with bone disease is managed in outpatient endocrinology or paediatrics with radiographs and a 3-month review. The acutely hypocalcaemic infant (seizure, stridor, cardiomyopathy) is admitted for IV calcium and high-dose vitamin D, monitored on a paediatric ward with cardiac telemetry. CKD-related deficiency is co-managed with nephrology through a CKD-MBD pathway. Failure to respond to adequate doses mandates a search for malabsorption, ongoing drug effect, non-adherence, or a phosphopenic/genetic rickets — the dose is right but the diagnosis is wrong. [1]

Long-term maintenance is lifelong in high-risk groups (dark skin, elderly, malabsorption, CKD, post-bariatric, anticonvulsants) because the underlying cause rarely resolves; relapse is the rule without continued supplementation. [1]

Special Populations

Infants and children — supplementation of breastfed infants from birth is the cornerstone of prevention: 400 IU/day in the first year achieves 25-OH-D over 50 nmol/L with good randomised-trial evidence. Premature infants need supplementation regardless of feeding because the fetal store is laid down in the third trimester.[11]

Pregnant and breastfeeding women — pregnant and lactating women are an at-risk group whose supplementation prevents neonatal hypocalcaemia and congenital rickets; where direct infant supplementation is impractical, maternal postpartum supplementation is a plausible substitute, with infant levels monitored. [12][14]

The elderly — combine vitamin D 700 to 1000 IU/day (the dose range that reduced falls by 19 per cent, RR 0.81, in pooled randomised trials) with adequate calcium (RDA 700 to 1300 mg/day) and falls-prevention advice. Cutaneous synthesis falls with age and housebound or institutionalised elderly are a priority supplementation group.[3][8]

CKD — needs calcitriol (or paricalcitol, alfacalcidol) because 1-alpha-hydroxylation is impaired; native colecalciferol alone is insufficient. Co-manage through a CKD-MBD pathway with phosphate binders and calcimimetics as needed. [1]

Dark skin, veiled or culturally covered patients, and immigrants to high latitudes — these are the priority groups for targeted supplementation and screening; sun-exposure advice must be culturally appropriate. The whole family is often deficient and should be screened and treated together. [12][15]

Obesity and post-bariatric patients — about 40 per cent higher vitamin D intake is needed in obesity to reach the same 25-OH-D; lifelong micronutrient surveillance after bariatric surgery. [16]

Anticonvulsant / rifampicin / antiretroviral therapy — enzyme inducers increase catabolism; higher maintenance dosing with monitoring, and review of the drug regimen where possible. [1]

Evidence, Guidelines & Regional Differences

The evidence base for vitamin D has been transformed in the last decade by a wave of large randomised controlled trials that tested whether supplementation reduces non-skeletal outcomes (cancer, cardiovascular disease, diabetes, falls, infections, mortality). The consistent answer has been no — vitamin D supplementation is a bone-health intervention, not a panacea. The regional guidelines have diverged on thresholds and maintenance doses, and these deltas are examinable.[2][6][7]

[6] [5] [4] [3] [7] [15] [11] [10] [8] [15] [2] [10] [12] [15] [11] [14] [12] [1]

The central controversy is whether low 25-OH-D is a cause or a consequence of poor health. Observational associations are abundant and striking — low 25-OH-D with cardiovascular disease, cancer, infections, autoimmunity, mortality — but Mendelian randomisation and the large RCTs (VITAL, ViDA) suggest most associations are reverse causation: illness, inflammation, obesity and immobility lower 25-OH-D rather than the reverse. The current evidence-based position is: vitamin D supplementation prevents and treats rickets, osteomalacia and (with calcium) secondary hyperparathyroidism, and modestly reduces falls in the elderly; it does not prevent cancer, cardiovascular disease, diabetes or infections in the generally replete population.[6][7]

Prevention

Prevention is simple, cheap and effective, and is the public-health centrepiece of the global response to nutritional rickets.[1]

Supplementation is the most reliable strategy: direct infant supplementation of 400 IU/day for breastfed infants in the first year, with targeted supplementation for pregnant and breastfeeding women, the elderly, those with limited sun exposure, and people with dark skin. Adherence is the practical limiting factor. [11][14][15]

Fortification of staple foods is the population-level strategy — economically the most cost-effective way forward — with systematic vitamin D food fortification (and/or calcium) advocated to avoid severe deficiency at population scale. The UK has historically relied on voluntary fortification only, which delivers an inconsistent dose. [12][15][1]

Sun exposure advice is culturally calibrated and latitude-aware: at Boston (42 degrees N) sunlight made no previtamin D3 in skin from November through February, and at Edmonton (52 degrees N) from October through March — so in winter at high latitudes, supplementation is essential. Advise sun exposure short of erythema, with longer exposure for darker skin. [13]

Maternal supplementation during lactation is a plausible alternative to direct infant dosing — recent trials achieved infant 25-OH-D similar to direct daily infant supplementation, though evidence remains weaker than for direct infant dosing. [14]

Monitoring

Recheck 25-OH-D at 3 to 4 months after starting loading therapy (the store takes this long to plateau). Confirm the level has reached 50 nmol/L or above; if not, investigate adherence, malabsorption, ongoing drug effect or a wrong diagnosis. Once stable, monitor annually in high-risk groups (CKD, malabsorption, post-bariatric, anticonvulsants, dark skin, elderly). Track calcium, phosphate, ALP and PTH to confirm biochemical healing — ALP and PTH normalise as rickets heals, often before radiographic resolution.[1][2]

In children, repeat wrist and knee radiographs at 3 months to document metaphyseal healing, and monitor growth (height velocity accelerates as rickets heals). In adults on calcitriol or alfacalcidol (CKD, hypoparathyroidism), check calcium every 1 to 2 weeks during dose titration to avoid hypercalcaemia and hypercalciuria, then every 3 to 6 months once stable. In CKD, follow the full CKD-MBD panel (calcium, phosphate, PTH, ALP, 25-OH-D) on a defined schedule. [1]

Red Flags

Exam application bank (NEET-PG / INICET)

One-line answer

Vitamin D deficiency is the commonest nutritional deficiency worldwide, caused by inadequate UVB skin synthesis, dark skin, malabsorption, CKD, liver disease, obesity and enzyme-inducing drugs. In the growing skeleton it causes nutritional rickets — craniotabes, rachitic rosary, Harrison sulcus, widened wrists, genu varum, delayed fontanelle closure and dental defects. In the mature skeleton it causes osteomalacia — diffuse bone pain, proximal muscle weakness, a waddling gait and Looser zones (pseudofractures). The diagnostic test is 25-hydroxyvitamin D (calcidiol) in at-risk patients: under 50 nmol/L (20 ng/mL) deficient, severe deficiency under 30 nmol/L (12 ng/mL), over 50 nmol/L the treatment goal, with the classical biochemical tetrad of low or normal calcium, low phosphate, high PTH (secondary hyperparathyroidism) and raised alkaline phosphatase. Treatment is high-dose cholecalciferol or ergocalciferol daily for at least 12 weeks (e.g. 50,000 IU weekly for 8 weeks) then maintenance, always with adequate calcium. [2][15][12][10]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Vitamin D Deficiency (Rickets & Osteomalacia).

Exam Pearls

References

1. [1]Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets J Clin Endocrinol Metab, 2016.PMID 26745253
2. [2]Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab, 2011.PMID 21646368
3. [3]Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials BMJ, 2009.PMID 19797342
4. [4]Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ, 2003.PMID 12609940
5. [5]Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study : A Randomized Clinical Trial JAMA Cardiol, 2017.PMID 28384800
6. [6]Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease N Engl J Med, 2019.PMID 30415629
7. [7]Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials Lancet Diabetes Endocrinol, 2017.PMID 29102433
8. [8]Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know J Clin Endocrinol Metab, 2011.PMID 21118827
9. [9]Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial JAMA, 2010.PMID 20460620
10. [10]Hassan AB, Hozayen RF, Alotaibi RA, et al. Therapeutic and maintenance regimens of vitamin D3 supplementation in healthy adults: A systematic review Cell Mol Biol (Noisy-le-grand), 2018.PMID 30511630
11. [11]Shaw NJ. Prevention and treatment of nutritional rickets J Steroid Biochem Mol Biol, 2016.PMID 26493853
12. [12]Uday S, Hogler W. Nutritional rickets & osteomalacia: A practical approach to management Indian J Med Res, 2020.PMID 33380700
13. [13]Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin J Clin Endocrinol Metab, 1988.PMID 2839537
14. [14]O'Callaghan KM, Taghivand M, Zuchniak A, et al. Vitamin D in Breastfed Infants: Systematic Review of Alternatives to Daily Supplementation Adv Nutr, 2020.PMID 31552417
15. [15]Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide Eur J Clin Nutr, 2020.PMID 31959942
16. [16]Dhaliwal R, Mikhail M, Feuerman M, et al. The vitamin D dose response in obesity Endocr Pract, 2014.PMID 25100366